Free Trial
NASDAQ:DRTS

Alpha Tau Medical Q4 2024 Earnings Report

Alpha Tau Medical logo
$10.37 +0.33 (+3.29%)
As of 04:00 PM Eastern

Alpha Tau Medical EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.13
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Alpha Tau Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alpha Tau Medical Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Alpha Tau Medical's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Sunday, August 9, 2026 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alpha Tau Medical Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS) is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.

View Alpha Tau Medical Profile